Tirosint Sollevothyroxine

101,557 adverse event reports submitted to the FDA (1997–2026)

This data reflects voluntary reports submitted to the FDA's Adverse Event Monitoring System (AEMS), formerly the FDA Adverse Event Reporting System (FAERS). A report does not mean the medication caused the event. Data may be incomplete or contain errors. Learn more about AEMS. New to this data? Read our guide on how to interpret FDA adverse event reports →
New to FDA adverse event data? Here's how to read these reports →

Top Reported Adverse Events

The most frequently reported events in association with Tirosint Sol in the FAERS database. These are events reported by patients taking this medication, not necessarily caused by it. A single report may include multiple events.

Show these terms with plain-language definitions

Tap any term below for a plain-language definition.

Browse the full glossary →

Ranked by frequency of reports, not severity. The most-reported event is not necessarily the most dangerous or the most common in patients taking this drug.

Who Is Reporting

Demographics of patients in FAERS reports that included this information. Not all reports include patient demographics.

By Sex

View reporter sex data as a table
Tirosint Sol adverse event reports by reporter sex
SexReports
Female71,431
Male22,148
Unknown91

By Age Group

View age group data as a table
Tirosint Sol adverse event reports by reporter age group
Age groupReports
0-171,376
18-342,747
35-497,929
50-6418,310
65-7416,207
75+17,823

This shows who filed reports, reflecting who takes this drug and who tends to report, not who is at greatest risk.

Reported Outcomes

Outcomes recorded in FAERS reports that included Tirosint Sol. A single report may involve multiple reactions, each with a different outcome. These categories are defined by FDA reporting guidelines, not by PillSignal.

View outcome data as a table
Tirosint Sol adverse event reports by reported outcome
OutcomeReports
Other Serious40,977
Hospitalization38,328
Non-Serious32,100
Death8,191
Life-Threatening5,938
Disability3,739

Serious outcomes are far more likely to be reported than mild ones, so this overstates how often outcomes are serious. A recorded death does not mean the drug caused it.

Number of FAERS reports received per quarter for Tirosint Sol. Changes in volume may reflect shifts in prescribing rates, media attention, or reporting behavior, not changes in the medication's safety profile.

View report trend as a table
Tirosint Sol adverse event reports by year
YearReports
19971
20042,045
20052,017
20062,182
20072,757
20084,016
20093,826
20104,309
20116,160
20126,851
20131,453
20141,807
20152,607
20163,440
20173,898
20184,514
20194,395
20205,897
20216,167
20227,726
20237,399
20247,719
20258,588
2026 (partial)1,783

The steep increase around 2004 reflects the FDA's move to electronic submission, not a change in this drug's safety. Trends track reporting volume, not risk.

Medications commonly reported with Tirosint Sol

In FDA adverse event reports that mention Tirosint Sol, these medications appeared most often in the same report.

This reflects co-occurrence in submitted reports, not evidence of drug interaction or combined risk. People often report several medications taken for the same condition or for unrelated reasons. Talk to a doctor or pharmacist about your specific medications.

Other medications with similar adverse event profiles in FDA FAERS reports.

Data Source

This data is sourced from the FDA's Adverse Event Monitoring System (AEMS), formerly FAERS, via the OpenFDA API. PillSignal is not affiliated with the FDA.

View this data on the FDA website →

Data last updated: June 2026